

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re the Application of: Stuart L. Schreiber, Peter
Belshaw, and Gerald R. Crabtree

Serial No. 08/922,240

Filed: 27 August 1997

Title: *Gene Therapy by Cell Specific Targeting*

Attorney Docket No: APV-007.01

Group Art Unit: 1804

Assistant Commissioner for Patents
Washington DC 20231
Attn: Corrections Branch

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, Attn: Corrections Branch, on the date indicated below.

4/10/98

Date

I. Clauss
Isabelle Clauss

REQUEST FOR CORRECTION OF FILING RECEIPT

Dear Sir:

The official filing receipt for the above-referenced patent application contains the following error: it fails to indicate that the application is a continuation-in-part of provisional patent application No. 60/024,666 filed on August 27, 1996. A copy of a declaration indicating the priority claim is attached hereto. Accordingly, please amend the official filing receipt by adding:

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A CIP OF PROVISIONAL PATENT APPLICATION NO. 60/024,666 08/27/96

A copy of the official filing receipt with these changes noted thereon is enclosed herewith.


Respectfully submitted,
FOLEY, HOAG & ELIOT LLP

I. Clauss

Isabelle M. Clauss, Ph.D.
Registration No. (see attached)
Agent for Applicants

Patent Group
FOLEY, HOAG & ELIOT LLP
One Post Office Square
Boston, MA 02109
(617) 832-1000
Date: 4/10/98

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

TJ

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/922,240	08/27/97	1804	\$0.00	APV-007.01	4	36	7

PATENT GROUP
FOLEY HOAG & ELIOT
ONE POST OFFICE SQUARE
BOSTON MA 02109

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

STUART L. SCHREIBER, BOSTON, MA; PETER J. BELSHAW,
SOMERVILLE, MA; GERALD CRABTREE, WOODSIDE, CA.

Continuing Data as claimed by Applicant:
this APPLN is a CON-IN-PART of Provisional Application No. 60/024,666 08/27/

FOREIGN FILING LICENSE GRANTED 10/09/97

TITLE
GENE THERAPY BY CELL SPECIFIC TARGETING

PRELIMINARY CLASS: 424

RECEIVED

OCT 14 1997

F.H. & E. LLP
PATENT DEPT.

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.62 which meets the provisions of 37 CFR 5.15(a). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



FOLEY, HOAG & ELIOT LLP
ONE POST OFFICE SQUARE
BOSTON, MASSACHUSETTS 02109-2170

1636

Isabelle M. Clauss, Ph.D.
Patent Agent/Technology Specialist
(617) 832-1177
imc@fhe.com

TELEPHONE 617-832-1000
FACSIMILE 617-832-7000
<http://www.fhe.com>

1615 L STREET, N.W., SUITE 850
WASHINGTON, D.C. 20036
TEL: 202-775-0600
FAX: 202-857-0140

April 10, 1998

Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application Serial No. 08/922,240
Entitled: *Gene Therapy by Cell Specific Targeting*
By: Stuart Schreiber et al.
Filed: August 27, 1997
Group Art Unit: 1805
Attorney Docket No.: APV-007.01



Dear Sir:

Enclosed for filing in the above-referenced patent application please find the following:

1. Transmittal of New Declaration, Petition and Power of Attorney;
2. One Declaration, Petition and Power of Attorney (G. Crabtree);
3. Request for Correction of Filing Receipt;
4. Copy of official Filing Receipt with changes marked thereon; and
5. Return mail room postcard.

The Commissioner is hereby authorized to charge any under-payments or credit any over-payments to our Deposit Account No. 06-1448. A duplicate of this sheet is enclosed.

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail on the date indicated below in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

4/10/98
Date

Isabelle Clauss
Isabelle Clauss

Respectfully submitted,
FOLEY, HOAG & ELIOT LLP

Isabelle Clauss
Isabelle M. Clauss, Ph.D.
Registration No. (See attached)
Agent for Applicants

APR 13 1998

APR 13 1998

APR 13 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Schreiber et al.

Serial No.: 08/922,240

Filed: August 27, 1997


For: *Gene Therapy by Cell Specific Targeting*

Attorney Docket No.: APV-007.01

Group Art Unit:

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231



Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date set forth below.

4/10/98

By: Isabelle

Isabelle

Date of Signature and Mail Deposit

TRANSMITTAL OF NEW DECLARATION, PETITION

AND POWER OF ATTORNEY

Dear Sir:

Applicants are submitting concurrently herewith an executed Declaration, Petition and Power of Attorney For Patent Application in the above-referenced application. Applicants have previously (March 13, 1998) submitted Declarations, Petitions and Powers of Attorney executed by each of the three inventors to the U.S. Patent and Trademark Office. These were received by the Patent Office, as indicated by the receipt date stamped return postcard. However, it was discovered after submission of these documents that one of the inventors (G. Crabtree) had inadvertently indicated the wrong date next to his signature (1997 instead of 1998). Accordingly, the attached Declaration is a new Declaration, Petition and Power of Attorney signed and dated correctly by the G. Crabtree.

303395.1

No fees are believed to be due in connection with this submission. However, if any fees are due, the Commissioner is hereby authorized to charge any fees or credit any over-payments to our Deposit Account No. 06-1448. A duplicate of this sheet is enclosed.

Respectfully submitted,
FOLEY, HOAG & ELIOT LLP

By: I. Clauss

Isabelle M. Clauss, Ph.D.
Agent for Applicants
Reg. No. (see attached)

One Post Office Square
Boston, MA 02109
Telephone: (617) 832-1000
Facsimile: (617) 832-7000
Date: 4/10/98



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Isabelle M. Clauss is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of the Foley, Hoag & Eliot, LLP, law firm to prepare and prosecute patent applications, wherein the applicants are clients of the Foley, Hoag & Eliot, LLP, law firm, and wherein a registered practitioner who is a member of the Foley, Hoag & Eliot, LLP, law firm is the attorney of record. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Isabelle M. Clauss ceases to lawfully reside in the United States, (ii) Isabelle M. Clauss' employment with Foley, Hoag & Eliot, LLP, law firm ceases or is terminated, or (iii) Isabelle M. Clauss ceases to remain or reside in the United States on a H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: April 16, 1998


Karen L. Bovard, Director
Office of Enrollment and Discipline